On December 8, 2005, we published an expression of concern1regarding an article by Bombardier et al. on the Vioxx GastrointestinalOutcomes Research (VIGOR) study that was published in the Journalon November 23, 2000.2 Our expression of concern was promptedby evidence that the VIGOR article did not accurately representthe safety data available to the authors when the article wasbeing reviewed for publication.
More than four months before the article was published, at leasttwo of its authors were aware of critical data on an array ofadverse cardiovascular events that were not included in theVIGOR . . . [Full Text of this Article]
Source Information
This letter was published at www.nejm.org on February 22, 2006.
This article has been cited by other articles:
Troy, D. E., Gottlieb, S., Kesselheim, A. S., Avorn, J.
(2008). Pharmaceutical Promotion and First Amendment Rights. NEJM
359: 536-537
[Full Text]
Greenland, S.
(2007). Commentary: On 'Quality in epidemiological research: should we be submitting papers before we have the results and submitting more hypothesis generating research?'. Int J Epidemiol
36: 944-945
[Full Text]
Psaty, B. M., Charo, R. A.
(2007). FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part. JAMA
297: 1917-1920
[Full Text]
Criner, G. J.
(2007). Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proc Am Thorac Soc
4: 171-175
[Abstract][Full Text]
Coultas, D.
(2007). Ethical Considerations in the Interpretation and Communication of Clinical Trial Results. Proc Am Thorac Soc
4: 194-199
[Abstract][Full Text]
Laine, C., Goodman, S. N., Griswold, M. E., Sox, H. C.
(2007). Reproducible Research: Moving toward Research the Public Can Really Trust. ANN INTERN MED
146: 450-453
[Abstract][Full Text]
Glick, M.
(2006). Opprobrium or opportunity?. Journal of the American Dental Association
137: 1484-1486
[Full Text]
Zhang, J., Ding, E. L., Song, Y.
(2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA
296: 1619-1632
[Abstract][Full Text]
DeAngelis, C. D.
(2006). The Influence of Money on Medical Science. JAMA
296: 996-998
[Full Text]
Psaty, B. M., Rennie, D.
(2006). Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry. JAMA
295: 2787-2790
[Full Text]
Dieppe, P.
(2006). Complicity theory: an explanation for the ;coxib problem'?. JRSM
99: 273-274
[Full Text]